The evolution of pathogens is a major challenge in the development and effectiveness of vaccines. As pathogens mutate, they may alter the antigens that trigger immune responses, potentially rendering previously developed vaccines less effective or ineffective against new strains. This is particularly evident in rapidly evolving viruses like influenza, HIV, and SARS-CoV-2. Mutations and genetic shifts in these viruses may lead to antigenic variation, meaning that the immune system may no longer recognize the pathogen in the same way. To address this issue, scientists are employing advanced techniques such as genomic surveillance and predictive modeling to track the evolution of pathogens and anticipate new variants. By understanding these evolutionary patterns, vaccine developers can design more adaptable and broad-spectrum vaccines that remain effective even as pathogens evolve, ensuring continued protection against emerging threats.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia